乌鸦传媒

<乌鸦传媒 class='mpt-top_cat_title'>Meeting Coverage >

ASCO

<乌鸦传媒>Adjuvant Anti-PD-1 Misses on OS in High-Risk Melanoma

But pembrolizumab topped active controls for relapse-free survival

<乌鸦传媒>Combination Shows Promise in Post-Osimertinib Lung Cancer

Responses in 36% with amivantamab-lazertinib, 47% with EGFR/MET resistance

<乌鸦传媒>Novel CDK 4/6 Inhibitor Proves Mettle in HR+/HER2- Advanced Breast Cancer

Dalpiciclib may be a new treatment option; palbociclib and ribociclib continue to shine

<乌鸦传媒>Perioperative Chemo Enough in Esophageal Cancer?

MAGIC/FLOT regimens yielded similar overall survival to multimodal CROSS regimen

<乌鸦传媒>CAR-T Drives High Response in Relapsed/Refractory ALL

ZUMA-3 study shows brexucabtagene autoleucel offers long-term clinical benefit

<乌鸦传媒>Antibody-Drug Conjugate Active in Resistant Lung Cancer

Responses in 39% of EGFR inhibitor-resistant patients with patritumab deruxtecan

<乌鸦传媒>Chemoimmunotherapy Tied to Better Outcomes in Advanced NSCLC

PD-L1 status and age play key roles in success of combined regimen versus immunotherapy alone

<乌鸦传媒>Combination Therapy Achieves High Response in Ph+ ALL

Ponatinib-blinatumomab offers promising regimen in frontline and relapse/refractory disease

<乌鸦传媒>Small PFS Bump in Synovial Sarcoma With Novel Drug

But questions raised over control arm and whether improvement represents a meaningful benefit

<乌鸦传媒>Radioligand Therapy Boosts Survival in Metastatic CRPC

PSMA-directed agent improved overall survival by median 4 months

<乌鸦传媒>Adding Chemo to Standard Care No Help for Cervical Cancer

Similar OS, PFS, and patterns of recurrence, with more toxicity

<乌鸦传媒>PD-1 Inhibitor Shows Benefit in Nasopharyngeal Cancer

Toripalimab plus first-line chemo improved survival in recurrent/metastatic disease

<乌鸦传媒>Olaparib Wins in Early BRCA-Mutant Breast Cancer

First trial to show adjuvant PARP inhibitor benefit inBRCA mutation carriers

<乌鸦传媒>Survival Boost With First-Line Immunotherapy for Esophageal Cancer

Nivolumab plus ipilimumab or chemo offers new option for advanced, metastatic disease

<乌鸦传媒>'A Quantum Leap Forward': Potential New Standard in High-Risk RCC

Adjuvant immunotherapy led to 32% reduction in the risk of recurrence, positive trend in OS

<乌鸦传媒>Vaccination, Screening Succeeds in Cervical and Prostate Cancers

Cervical cancer rates on the decline; PSA testing benefits younger Black men

<乌鸦传媒>PD-L1 Inhibitor Thwarts Recurrence in Early Lung Cancer

Risk of death, recurrence 34% lower with atezolizumab after surgery and chemo

<乌鸦传媒>Novel Immunotherapy Boosts Melanoma Outcomes

Adding LAG-3 checkpoint inhibitor to nivolumab extended PFS in patients with advanced disease

<乌鸦传媒>High Marks for CAR T Cells in R/R Myeloma

Response rates of 70-100% with BCMA-targeted products for heavily treated disease

<乌鸦传媒>Second Surgery Gets OS Win in Recurrent Ovarian Cancer

Survival improved by nearly 8 months with cytoreductive surgery at first relapse

<乌鸦传媒>Early Palliation: Boon for AML Patients on Intensive Chemo

Intervention led to marked improvements in QoL, mental distress, end-of-life care

<乌鸦传媒>Pembrolizumab May Help in Triple-Negative Breast Cancer

Upfront therapy extends progression-free survival in metastatic disease, study shows

<乌鸦传媒>Surgery for Metastatic Breast Cancer Fails to Boost Overall Survival

Cumulative data, though, don't rule out benefit for selected patients with de novo stage IV disease

<乌鸦传媒>Add-On Tucatinib Ups Survival in Breast Cancer With Brain Mets

TKI plus trastuzumab-capecitabine reduced risk of death by nearly half

<乌鸦传媒>VRd Still Reigns in Newly Diagnosed Myeloma

KRd fails to prove superiority in head-to-head trial

<乌鸦传媒>CAR T-Cell Therapy Impresses in Indolent NHL

Overall response rate exceeding 90% with axi-cel in relapsed/refractory setting

<乌鸦传媒>Oral ADT Slashes Heart Risk in Advanced Prostate Cancer

Novel GnRH antagonist has potential to be new standard, says researcher

<乌鸦传媒>Sentinel Node Biopsy Proves Mettle in H&N Cancer

Senti-MER study results establish SN biopsy as standard of care, researcher says

<乌鸦传媒>Studies Make Case for Hormonal Therapy in nmCRPC

Prolonged survival with three different androgen signaling inhibitors

<乌鸦传媒>HCQ Linked to Harm in Cancer Patients

Combination with azithromycin associated with three-fold risk of mortality, registry study shows

<乌鸦传媒>COVID-19 in Thoracic Cancer Patients a Killer

Most cancer patients hospitalized

<乌鸦传媒>New First-Line Standard in Metastatic Bladder Cancer

"High bar to beat" as avelumab maintenance improves median survival by over 7 months

<乌鸦传媒>Paradigm Shift Coming for Early NSCLC?

Postoperative osimertinib doubles DFS in patients with stages Ib-IIIa EGFR+ lung cancer

<乌鸦传媒>CAR T Cells Show Activity in Solid Tumors

High response rate in mesothelioma, shrinkage of gastric, pancreatic tumors

<乌鸦传媒>Keytruda 'Switch' Extends PFS in Advanced Bladder Cancer

Matthew Galsky, MD, discusses possible role of maintenance PD-1 blockade

<乌鸦传媒>Jury Out on Margetuximab in Advanced HER2+ Breast Cancer

One-month PFS boost, but certain subgroups may derive more benefit

<乌鸦传媒>Depth of Tumor Response a Better Survival Predictor

Could improve on RECIST as outcome measure in oncology

<乌鸦传媒>Preop Chemo Reduces CRC Surgical Morbidity

Lower 2-year recurrence rate versus adjuvant therapy but not significantly

<乌鸦传媒>Good News Continues for Enfortumab Vedotin in Bladder Ca

Phase II trial offers longer survival in difficult disease

<乌鸦传媒>'Unprecedented' Survival Benefit Vanishes in Confirmatory Cancer Trial

Over $500 million in sales for drug with possibly no benefit

3